Brokerages Set Outset Medical, Inc. (NASDAQ:OM) PT at $10.00

Outset Medical, Inc. (NASDAQ:OM) has received an average rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $10.00.

Several analysts recently commented on OM shares. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. TD Cowen reissued a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Wednesday, June 24th.

Insider Buying and Selling at Outset Medical

In related news, CFO Renee Gaeta sold 17,672 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Following the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 25,337 shares of company stock worth $115,660. 2.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BML Capital Management LLC grew its position in shares of Outset Medical by 250.2% during the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after acquiring an additional 1,359,021 shares during the period. Alyeska Investment Group L.P. increased its stake in shares of Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after purchasing an additional 150,000 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in Outset Medical by 71.8% in the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock worth $2,078,000 after purchasing an additional 234,082 shares during the period. Assenagon Asset Management S.A. raised its holdings in Outset Medical by 34.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after purchasing an additional 131,381 shares during the period. Finally, Millennium Management LLC boosted its position in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock worth $5,950,000 after purchasing an additional 262,874 shares in the last quarter.

Outset Medical Price Performance

Shares of OM opened at $4.04 on Friday. The business’s 50-day moving average is $4.50 and its two-hundred day moving average is $4.27. The company has a market capitalization of $74.90 million, a P/E ratio of -0.97 and a beta of 1.95. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.97 and a current ratio of 6.29. Outset Medical has a fifty-two week low of $3.00 and a fifty-two week high of $18.63.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The company had revenue of $27.86 million for the quarter, compared to analysts’ expectations of $28.90 million. Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. Research analysts predict that Outset Medical will post -3.82 earnings per share for the current year.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.